FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
PR Newswire•31/07/2026•17:34 ET
0
Key Highlights
- ➤CYWC628 first patients dosed in Phase 1/2 diabetic foot ulcer trial; interim results expected 2H 2026.
- ➤CYWC628 primary safety and efficacy results expected by end-2026.
- ➤$9.0 million private placement includes $3.0 million upfront and approximately $6.0 million potential warrant proceeds.
- ➤$3.0 million public offering closed, strengthening FibroBiologics (FBLG) financing.
- ➤Q2 R&D expenses approximately $1.7 million, down from approximately $2.0 million year over year.
- ➤Q2 net loss approximately $4.1 million; cash and equivalents approximately $3.5 million at June 30, 2026.
- ➤CYPS317 psoriasis IND clearance anticipated Q4 2026; CYMS101 multiple sclerosis IND submission planned Q4 2026.
- ➤Three CYWC628 batches manufactured under FDA cGMP; two released, third pending safety and quality testing.
Expert Statements
Pete O'Heeron, CEO and Founder of FibroBiologics
“With the first patient dosed in our CYWC628 trial, FibroBiologics has entered an important stretch as a clinical-stage company. Every milestone ahead builds on this one, and every data point will speak to what fibroblasts can do for patients. We are positioned for the catalysts ahead and eager to share our initial findings this year.”
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On track for interim results reporting in 2H 2026
Get started
Create a free account to read the full story.